A Study Evaluating Veliparib as a Single Agent or in Combination With Chemotherapy in Subjects With Solid Tumors

Exclusion Criteria

• •Subject has a clinically significant and uncontrolled major medical condition(s) including but not limited to:
• •Uncontrolled seizure disorder, including focal or generalized seizure within the last 12 months;
• •Uncontrolled nausea/vomiting/diarrhea;
• •Active uncontrolled infection;
• •Symptomatic congestive heart failure;
• •Unstable angina pectoris or cardiac arrhythmia;
• •Psychiatric illness/social situation that would limit compliance with study requirements;
• •Any medical condition, which in the opinion of the study investigator, places the subject at an unacceptably high risk for toxicities.
• •Subjects who have hypersensitivity to Carboplatin, Paclitaxel or Cremophor should be excluded from arm B.
• •Subject has received any of the following anti-cancer therapies 21 days prior to the first dose of study drug or a biologic agent for anti-neoplastic intent within 30 days prior to the first dose of study drug.
• •Subject who requires parenteral nutrition, tube feeding or has evidence of a partial bowel obstruction or perforation within 28 days prior to study drug.
• •The subject has had another active malignancy within the past 3 years except for any cancer in situ that the Principal Investigator considers to be cured.